Case Report
A 6-year-old African American female (Pt1) and 26-year-old Hispanic female (Pt2) patients, both with CF, respiratory cultures positive for MDR P. aeruginosa, and advanced lung disease, were treated with personalized inhaled phage therapy directed against each of their respective P. aeruginosa lung infections at Children’s National Hospital (Washington, DC). Pt1 was not eligible for CFTR modulator therapy; Pt2 was started on elexacaftor-tezacaftor-ivacaftor but did not have a significant response to therapy. Pt1 had received more than 30 days of antibiotic therapy and remained in the pediatric intensive care unit (PICU) where she required continuous noninvasive ventilation and oxygen supplementation. Pt2 had a significant decline in clinical stability over the preceding 12 months, requiring 5 hospitalizations for treatment of pulmonary exacerbations in addition to multiple outpatient courses of intravenous (IV) and oral antibiotics…
Read here: https://journals.sagepub.com/doi/full/10.1177/23247096231188243
PHAGElogist 